DILIN - Prospective Study

Recruiting now

Conditions studied: Liver Diseases

In brief

The purpose of this study is to identify individuals who have suffered a liver injury arising as an idiosyncratic reaction to a prescription drug or a complementary and alternative medicine. Recently added acute cases enrollment that meets criteria to the protocol. Also added Fibroscans to the protocol that will be completed at baseline and follow-up on chronic subjects.

Key facts

Study ID

NCT00345930

Run by

Duke University

People needed

4000

Starts

2004-09-01

Expected to finish

2028-07-31

Last updated by the study team

2026-04-08

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age > 2 years at enrollment into the study.
• Evidence of liver injury that is known or suspected to be related to consumption of a drug or CAM product in the 6-month period prior to enrollment.
• Written Informed consent from the patient or the patient's legal guardian.
• Documented clinically important DILI, defined as any of the following:
• ALT or AST >5 x ULN or A P'ase >2 x ULN confirmed on at least 2 consecutive blood draws in patients with previously normal values.
• If baseline (BL) ALT, AST or A P'ase are known to be elevated, then ALT or AST >5 x BL or A P'ase >2 x BL on at least 2 consecutive blood draws. "Baseline" is defined as the average of at least 2 measurements performed during the 12-month period prior to starting the DILI medication.
• Any elevation of ALT, A P'ase, or AST, associated with (a) increased total bilirubin [ ≥ 2.5 mg/dL], in absence of prior diagnosis of liver disease, Gilbert's syndrome, or evidence of hemolysis or (b) coagulopathy with INR > 1.5 in absence of coumadin therapy or known vitamin K deficiency.

You may not qualify if…

• Patients with any of the following will not be eligible for participation:
• Competing cause of acute liver injury such as hepatic ischemia that is felt by the investigator to be the primary reason for observed liver injury and supported by laboratory tests, serologies, liver biopsy, or radiology.
• Known, pre-existing autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, or other chronic biliary tract disease which may confound the ability to make a diagnosis of DILI.
• Acetaminophen hepatotoxicity.
• Liver/bone marrow transplant prior to the development of drug- or CAM-induced liver injury.

Where it is running

• University of Southern California — Los Angeles, California, United States (enrolling)
• Indiana University — Indianapolis, Indiana, United States (enrolling)
• NIH Clinical Site — Bethesda, Maryland, United States (enrolling)
• University of Michigan — Ann Arbor, Michigan, United States (enrolling)
• Univeristy of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States (enrolling)
• Thomas Jefferson — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.